60,115 Shares in HCA Healthcare, Inc. (NYSE:HCA) Purchased by Galvin Gaustad & Stein LLC

Galvin Gaustad & Stein LLC purchased a new position in HCA Healthcare, Inc. (NYSE:HCA) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 60,115 shares of the company’s stock, valued at approximately $18,044,000. HCA Healthcare makes up 1.6% of Galvin Gaustad & Stein LLC’s investment portfolio, making the stock its 21st biggest position.

A number of other institutional investors have also recently bought and sold shares of HCA. Terra Nova Asset Management LLC grew its stake in HCA Healthcare by 0.3% during the 3rd quarter. Terra Nova Asset Management LLC now owns 8,112 shares of the company’s stock valued at $3,297,000 after acquiring an additional 26 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its stake in HCA Healthcare by 7.4% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 421 shares of the company’s stock valued at $171,000 after acquiring an additional 29 shares in the last quarter. Waldron Private Wealth LLC grew its stake in HCA Healthcare by 1.8% during the 3rd quarter. Waldron Private Wealth LLC now owns 1,681 shares of the company’s stock valued at $683,000 after acquiring an additional 29 shares in the last quarter. Brookstone Capital Management grew its stake in HCA Healthcare by 0.7% during the 3rd quarter. Brookstone Capital Management now owns 4,065 shares of the company’s stock valued at $1,652,000 after acquiring an additional 30 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of HCA Healthcare by 2.4% during the 3rd quarter. UMB Bank n.a. now owns 1,301 shares of the company’s stock valued at $529,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

HCA opened at $324.43 on Thursday. The stock has a market cap of $82.18 billion, a PE ratio of 14.57, a P/E/G ratio of 1.08 and a beta of 1.64. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. HCA Healthcare, Inc. has a 1 year low of $278.68 and a 1 year high of $417.14. The stock’s 50 day simple moving average is $314.50 and its 200-day simple moving average is $352.84.

HCA Healthcare Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 27th. Stockholders of record on Friday, December 13th were given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date was Friday, December 13th. HCA Healthcare’s dividend payout ratio is presently 11.85%.

Insider Buying and Selling at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares in the company, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the transaction, the senior vice president now directly owns 52,702 shares in the company, valued at approximately $18,445,700. This represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Morgan Stanley reduced their price target on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. KeyCorp reduced their price target on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. Barclays reduced their target price on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Truist Financial reduced their target price on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $385.27.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.